Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance

INTRODUCTION: HER2 overexpression/amplification is identified in up to 40% of uterine serous carcinomas (USC) and 10% of ovarian serous carcinomas (OSC). However, clinical trials using various HER2-targeted agents failed to show significant responses. FDA-approved HER2 assays target only the protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvajal-Hausdorf, Daniel E., Schalper, Kurt A., Bai, Yalai, Black, Jonathan, Santin, Alessandro D., Rimm, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941302/
https://www.ncbi.nlm.nih.gov/pubmed/28196634
http://dx.doi.org/10.1016/j.ygyno.2017.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941302/
https://www.ncbi.nlm.nih.gov/pubmed/28196634
http://dx.doi.org/10.1016/j.ygyno.2017.02.002

Ejemplares similares